secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001193125-26-097467
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharma reports $72.2M neffy sales in first full year; net loss $171.3M
--------------------------------------------------------------------------

- Full-year U.S. neffy net product revenue $72.2M; total revenue $84.3M including $9.7M partner revenue.
- FY 2025 net loss $171.3M ($1.74/sh); Q4 net loss $41.3M ($0.42/sh).
- Cash $245.0M at Dec 31, 2025; expects to fund operations through cash-flow break-even.
- Sales force to expand from 106 to 150 in Q2 2026; >22,500 HCPs prescribed neffy, 50% repeat.
- Phase 2b CSU trial interim data H2 2026; Canada approval expected Q2 2026 with ALK.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312526097467/0001193125-26-097467-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312526097467/spry-20260309.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-097467

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer